In 2009, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial reported no difference in prostate cancer‐specific mortality in screened and unscreened men and the European Randomized Study of Screening for Prostate Cancer (ERSPC) found a small benefit for routine PSA screening 3, 4. This evidence concerns the gene KLK3 and Familial prostate cancer.